3D models of uveal melanoma offer hope for improved treatments
Source: Mayo Clinic News Network, January 2025
Mayo Clinic researchers have developed organoid models to study uveal melanoma, one of the most common types of eye cancer in adults. Their goal is to use these models to better understand how this disease works and develop treatments for unmet patient needs.
Organoids are 3D models grown from patient tissue that accurately reflect a patient’s unique genetic and biological characteristics, also known as “avatars." When derived from a patient’s cancer tumor, an organoid will behave and respond to treatments outside the body in a lab (in vitro) just like the original tumor would inside the body (in vivo).
In 50% of patients, uveal melanoma metastasizes, spreading to other parts of the body, leading to a poor prognosis and average survival of less than two years. Unfortunately, current treatments for this condition often have limited effectiveness, leaving patients and their doctors with few options.